ES2549209R1 - Partículas víricas VSV-VIH que carecen de la funcionalidad transcriptasa inversa y aplicaciones terapéuticas de las mismas - Google Patents

Partículas víricas VSV-VIH que carecen de la funcionalidad transcriptasa inversa y aplicaciones terapéuticas de las mismas Download PDF

Info

Publication number
ES2549209R1
ES2549209R1 ES201590017A ES201590017A ES2549209R1 ES 2549209 R1 ES2549209 R1 ES 2549209R1 ES 201590017 A ES201590017 A ES 201590017A ES 201590017 A ES201590017 A ES 201590017A ES 2549209 R1 ES2549209 R1 ES 2549209R1
Authority
ES
Spain
Prior art keywords
vsv
lack
reverse transcriptase
viral particles
therapeutic applications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201590017A
Other languages
English (en)
Other versions
ES2549209A2 (es
ES2549209B1 (es
Inventor
Sonsoles SÁNCHEZ-PALOMINO
Carmen ÁLVAREZ FERNÁNDEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IrsiCaixa Institut de Recerca de la Sida
Esteve Pharmaceuticals SA
Original Assignee
IrsiCaixa Institut de Recerca de la Sida
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IrsiCaixa Institut de Recerca de la Sida, Laboratorios del Dr Esteve SA filed Critical IrsiCaixa Institut de Recerca de la Sida
Publication of ES2549209A2 publication Critical patent/ES2549209A2/es
Publication of ES2549209R1 publication Critical patent/ES2549209R1/es
Application granted granted Critical
Publication of ES2549209B1 publication Critical patent/ES2549209B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15061—Methods of inactivation or attenuation
    • C12N2740/15062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Partículas víricas VSV-VIH que carecen de la funcionalidad transcriptasa inversa y aplicaciones terapéuticas de las mismas.#La presente invención se refiere al desarrollo de viriones no replicativos que tienen una mutación en la secuencia que codifica la proteína RT y que comprenden un genoma de un virus de la inmunodeficiencia humana (VIH) y vehiculizados por la proteína G de un virus de la estomatitis vesicular (VSV). Dichos viriones son útiles en medicina, concretamente para su uso en la generación de vacunas y más concretamente para el tratamiento del SIDA. Además la presente invención se refiere a un método para obtener una vacuna personalizada.
ES201590017A 2012-09-04 2013-09-04 Partículas víricas VSV-VIH que carecen de la funcionalidad transcriptasa inversa y aplicaciones terapéuticas de las mismas Expired - Fee Related ES2549209B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382340.3A EP2703482A1 (en) 2012-09-04 2012-09-04 VSV-HIV viral particles lacking reverse transcriptase functionality and therapeutic applications thereof
EP12382340 2012-09-04
PCT/EP2013/068296 WO2014037409A1 (en) 2012-09-04 2013-09-04 Vsv-hiv viral particles lacking reverse transcriptase functionality and therapeutic applications thereof

Publications (3)

Publication Number Publication Date
ES2549209A2 ES2549209A2 (es) 2015-10-26
ES2549209R1 true ES2549209R1 (es) 2016-03-10
ES2549209B1 ES2549209B1 (es) 2016-09-26

Family

ID=47044933

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201590017A Expired - Fee Related ES2549209B1 (es) 2012-09-04 2013-09-04 Partículas víricas VSV-VIH que carecen de la funcionalidad transcriptasa inversa y aplicaciones terapéuticas de las mismas

Country Status (3)

Country Link
EP (1) EP2703482A1 (es)
ES (1) ES2549209B1 (es)
WO (1) WO2014037409A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019246056A1 (en) * 2018-06-18 2019-12-26 University Of Miami Recombinant herpesviral vector

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500623B1 (en) * 1998-05-12 2002-12-31 Genecure Llp Replication defective HIV vaccine
EP1752541A1 (en) * 2004-05-10 2007-02-14 Fundaci n para la investigaci n y la prevenci n de Novel hiv-based recombinant viral clones and use thereof in analytical methods
WO2012136831A1 (en) * 2011-04-07 2012-10-11 Fundació Clinic Per A La Recerca Biomèdica Non-replicative virions of human immunodeficiency virus and therapeutic applications thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500623B1 (en) * 1998-05-12 2002-12-31 Genecure Llp Replication defective HIV vaccine
EP1752541A1 (en) * 2004-05-10 2007-02-14 Fundaci n para la investigaci n y la prevenci n de Novel hiv-based recombinant viral clones and use thereof in analytical methods
WO2012136831A1 (en) * 2011-04-07 2012-10-11 Fundació Clinic Per A La Recerca Biomèdica Non-replicative virions of human immunodeficiency virus and therapeutic applications thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALVAREZ-FERNANDEZ, C. et al. Generation and characterization of retroviral vectors based on HIV-1 genome as novel immunogens. AIDS Vaccine 2011. Bangkok, Thailand. Septiembre 2011. P11.05. [en línea][recuperado el 01.03.2016]Recuperado de internet:< http://www.vaccineenterprise.org/conference/2011/sites/default/files/poster%20tailand.pdf> *
CANKI, M. et al. Highly productive infection with pseudotyped human immunodeficiency virus type 1 (HIV-1) indicates no intracellular restrictions to HIV-1 replication in primary human astrocytes. Journal of Virology. Septiembre 2001, Vol.75, Nº 17, páginas: 7925 - 7933. ISSN 0022-538X <Doi:10.1128/JVI.75.17.7925-7933.2001> *
GRANELLI-PIPERNO, A. et al. Dendritic cells, infected with vesicular stomatitis virus-pseudotyped HIV-1, present viral antigens to CD4 and CD8 T cells from HIV-1-infected individuals. Journal of Immunology. Diciembre 2000, Vol. 165, Nº 11, páginas: 6620 - 6626. ISSN 0022-1767 (Impreso) *
RUFFIN, N. et al. Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011. Journal of Translational Medicine. Julio 2012, Vol. 10, Nº 1, página: 144. ISSN 1479-5876. <Doi:10.1186/1479-5876-10-144> *

Also Published As

Publication number Publication date
EP2703482A1 (en) 2014-03-05
WO2014037409A1 (en) 2014-03-13
ES2549209A2 (es) 2015-10-26
ES2549209B1 (es) 2016-09-26

Similar Documents

Publication Publication Date Title
CY1124756T1 (el) Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας
CY1122291T1 (el) Αναστολeις ιικου αναδιπλασιασμου
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
CR20130424A (es) Terapéuticos a base de levadura para infección de la hepatitis b crónica
CY1119896T1 (el) Μεθοδοι για αγωγη toy hcv
CY1117971T1 (el) Μακροκυκλικες πουρινες για την θεραπευτικη αντιμετωπιση ιικων λοιμωξεων
MD3718565T2 (ro) Vaccinuri împotriva virusului respirator
MX2016014642A (es) Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
NZ732391A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CO6460701A2 (es) Métodos y composiciones para inmunización contra virus
ES2510940R1 (es) Composición farmacéutica combinada y su uso para preparar un medicamento destinado al tratamiento y prevención de las enfermedades infecciosas
WO2013006688A3 (en) N-terminal deleted gp120 immunogens
EA201290956A1 (ru) Вакцина против вич
HRP20211749T1 (hr) Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom
EA201690146A1 (ru) Лекарственное средство, содержащее фармацевтическую комбинацию долутегравира, эмтрицитабина и тенофовира
MY194471A (en) Dihydropyrimidine compound and preparation method and use thereof
AR101814A1 (es) Partícula de tipo virus flavivirus
CO7030958A2 (es) Compuestos sustituidos de bencilamina, su uso en medicina, y en particular en el tratamiento de la infección del virús de la hepatitis c (vch)
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
CO6700818A2 (es) Vectores de parapoxvirus
EA201592298A1 (ru) Полуживая вирусная вакцина против респираторно-синцитиального вируса
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
ES2549209B1 (es) Partículas víricas VSV-VIH que carecen de la funcionalidad transcriptasa inversa y aplicaciones terapéuticas de las mismas
CL2015003752A1 (es) Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico
AR093341A1 (es) Antigenos vacunales quimericos contra el virus de la hepatitis c

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2549209

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20160926

FD2A Announcement of lapse in spain

Effective date: 20210915